Takeaways: Elahere’s pCPA agreement advances AbbVie’s efforts to expand access to targeted treatment for FRα-positive, platinum-resistant ovarian cancer in Canada. Its demonstrated overall survi...
Takeaways: The pCPA Letter of Intent for Anzupgo (delgocitinib cream) moves Canada closer to public reimbursement for the first topical therapy specifically indicated for moderate to severe chro...
Takeaways: CDA-AMC’s conditional reimbursement recommendation for Yorvipath moves the therapy closer to public funding in Canada for adults with chronic hypoparathyroidism who are not ...
